Meagen Salinas, MD
Neurology · Englewood, CONPI 1508209875
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,027 of the $23,870 with a category attached, or 67.1%. 19 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 49.2% of the total. 2025 is the largest year on record at $21,714, more than ten times the $664 reported in 2019.
Across 152 payments — averaging $157.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$12K
- H. Lundbeck A S$5K
- MDD US Operations, LLC$2K
- Boston Scientific$1K
- AbbVie$1K
- Acadia Pharmaceuticals Inc$416
- plus $2K from 13 others
Across 56 payments — averaging $23,568 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$726K
- H. Lundbeck A S$346K
- Genentech, Inc.$169K
- Roche TCRC, Inc.$58K
- AbbVie$16K
- UCB SA$5K
What the payments were for
- Speaking & faculty fees$16,02767%
- Travel & lodging$1,8978%
- Food & beverage$5,93825%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 20 | $11,746 |
| H. Lundbeck A S | 5 | $5,005 |
| MDD US Operations, LLC | 20 | $2,148 |
| Boston Scientific | 11 | $1,434 |
| AbbVie | 32 | $1,024 |
| Acadia Pharmaceuticals Inc | 14 | $416 |
| Abbott | 7 | $404 |
| Medtronic(2 entities) | 8 | $391 |
| Neurocrine Biosciences, Inc. | 10 | $376 |
| Ipsen Biopharmaceuticals, Inc | 6 | $300 |
| Merz Pharmaceuticals, LLC | 6 | $132 |
| Eli Lilly | 1 | $123 |
| Acorda Therapeutics, Inc | 1 | $104 |
| Cala Health, Inc. | 4 | $80 |
| Biogen | 3 | $69 |
| Revance Therapeutics, Inc. | 1 | $51 |
| Cycle Pharmaceuticals Inc | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,870 in reported general payments places this provider in the 80th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 13 | $12,092 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 33 | $554 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 21 | $410 |
| Donepezil Hcl | 15 | $43 |
Paid to pharmacies, not to this prescriber.
Other neurology in Englewood
- Rajeev KumarEnglewood$955K
- Marc TreihaftEnglewood$673K
- Cori MillenEnglewood$198K
- Kirsten BrachtEnglewood$151K
- Aaron HaugEnglewood$57K
- Karen KarwaEnglewood$52K
- Kevin PatelEnglewood$26K
- Tamara MillerFort Collins$1.4M
- Justin MoonDenver$1.4M
- Ravi ShahParker$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.